US 10,646,568 B2 · Targeting immunotherapy for amyloidosis

Abstract

Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.

Claims19

Dependent claims

A method of targeting an amyloid deposit for clearance, comprising:

contacting an amyloid deposit of a first amyloid type with an amyloid-reactive fusion peptide, wherein the amyloid-reactive fusion peptide comprises (i) an amyloid-reactive peptide at least 95% identical to any one of the amino acid sequences set forth as SEQ ID NOS:
1-17 and (ii) an X1-ED-X2 amino acid sequence epitope (SEQ ID NO:
53), wherein X1 and X2 are any amino acid;
and,
contacting the amyloid-reactive fusion peptide with an antibody or functional fragment thereof, wherein the antibody or functional fragment thereof is immunoreactive to a second amyloid type that is different than the first amyloid type and wherein the X1-ED-X2 epitope (SEQ ID NO:
53) of the amyloid-reactive fusion peptide directs the antibody or functional fragment thereof to the first amyloid type, thereby targeting the amyloid deposit of the first amyloid type for clearance.

3 more elements

Dependencies are inferred from the claim text.

Targeting immunotherapy for amyloidosis

Life of this patent

Targeting immunotherapy for amyloidosis

Life of this patent

Abstract

Claims19